Neumora Therapeutics, Inc. (NASDAQ:NMRA) Holdings Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 139.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 698,255 shares of the company's stock after purchasing an additional 406,891 shares during the period. Charles Schwab Investment Management Inc. owned about 0.44% of Neumora Therapeutics worth $9,224,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Callan Capital LLC raised its position in shares of Neumora Therapeutics by 222.6% in the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company's stock valued at $6,500,000 after purchasing an additional 456,207 shares in the last quarter. Auour Investments LLC acquired a new position in shares of Neumora Therapeutics in the 3rd quarter valued at approximately $3,302,000. Bank of New York Mellon Corp raised its position in shares of Neumora Therapeutics by 474.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company's stock valued at $2,316,000 after purchasing an additional 194,559 shares in the last quarter. TD Asset Management Inc increased its holdings in shares of Neumora Therapeutics by 31.6% in the 2nd quarter. TD Asset Management Inc now owns 144,994 shares of the company's stock valued at $1,425,000 after acquiring an additional 34,800 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Neumora Therapeutics in the 2nd quarter valued at approximately $1,323,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Trading Up 0.2 %

NMRA traded up $0.02 during trading on Tuesday, reaching $10.39. 721,208 shares of the company were exchanged, compared to its average volume of 743,239. The stock has a market cap of $1.68 billion, a P/E ratio of -5.48 and a beta of 3.37. The firm has a 50 day moving average of $12.31 and a 200 day moving average of $11.49. Neumora Therapeutics, Inc. has a 52 week low of $8.33 and a 52 week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.06). During the same period in the previous year, the company posted ($1.14) earnings per share. As a group, analysts forecast that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NMRA has been the subject of a number of research analyst reports. Royal Bank of Canada reiterated an "outperform" rating and issued a $29.00 price target on shares of Neumora Therapeutics in a report on Friday, November 22nd. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Neumora Therapeutics in a report on Wednesday, November 13th. JPMorgan Chase & Co. downgraded Neumora Therapeutics from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $23.00 price target on shares of Neumora Therapeutics in a report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $21.67.

Insider Buying and Selling

In other news, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total value of $83,500.63. Following the completion of the transaction, the insider now owns 322,966 shares of the company's stock, valued at approximately $4,847,719.66. This represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Matthew K. Fust sold 14,049 shares of the company's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the sale, the director now owns 20,100 shares of the company's stock, valued at approximately $342,303. This trade represents a 41.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,400 shares of company stock worth $686,361 in the last three months. 26.40% of the stock is owned by insiders.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.